Cardiovascular Atherosclerosis: Prediction, Prevention and Management


New Concepts in Dyslipidemia: Dispelling 10 Common Health “Truths” About Lipids and Risk Assessment

Dr. Douglas Triffon discusses HDL-C and LDL-C in relation to cardiovascular disease risk.
Douglas Triffon, MD, FACC, FNLA, FASE

Douglas Triffon, MD, FACC, FNLA, FASE

Scripps Center for Integrative Medicine
Medical Director, Lipid Clinic
Scripps Clinic
La Jolla, California

Influence of Elevated Triglycerides on Atherosclerosis and Non-Statin Therapies - Review of Data: Omega 3, Bempedoic Acid, Niacin, Ezetimibe, PCSK9 Inhibitors

Dr. David Cork reviews select non-statin pharmacotherapies and presents recent clinical trial data.
David Cork, MD, FACC, FNLA

David Cork, MD, FACC, FNLA

Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California

Evaluation of Subclinical Coronary Atherosclerosis, Coronary CTA and Coronary Calcium Score

Dr. Jorge Gonzalez discusses using coronary artery calcium scores as they relate to risk of death, development of coronary artery disease, and cardiovascular outcomes.
Jorge Gonzalez, MD, FACC

Jorge Gonzalez, MD, FACC

Director, Advanced Cardiovascular Imaging
Director, Hypertrophic Cardiomyopathy and Aorta Programs
Scripps Clinic
La Jolla, California

Panel Discussion/Q&A 1

Drs. Cork, Gonzalez and Triffon answer questions from course participants.
David Cork, MD, FACC, FNLA

David Cork, MD, FACC, FNLA

Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California
Jorge Gonzalez, MD, FACC

Jorge Gonzalez, MD, FACC

Director, Advanced Cardiovascular Imaging
Director, Hypertrophic Cardiomyopathy and Aorta Programs
Scripps Clinic
La Jolla, California
Douglas Triffon, MD, FACC, FNLA, FASE

Douglas Triffon, MD, FACC, FNLA, FASE

Scripps Center for Integrative Medicine
Medical Director, Lipid Clinic
Scripps Clinic
La Jolla, California

Exercise and Cardiovascular Risk

Dr. Christopher Suhar details how good lifestyle choices such as proper diet and exercise reduce cardiovascular disease risk.
Christopher Suhar, MD

Christopher Suhar, MD

Division Head, Scripps Center for Integrative Medicine
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California

Cardiovascular Prevention in Women

Dr. Poulina Uddin addresses the signs and risk factors of cardiovascular disease that are unique to women and offers preventive treatment options.
Poulina Uddin, MD

Poulina Uddin, MD

Director, Scripps Women’s Heart Center
General and Invasive Cardiology
Integrative and Holistic Medicine
Scripps Mercy Hospital San Diego
Scripps Clinic
La Jolla, California

Optimizing Dietary Pattern in Patients with Cardiovascular Disease

Dr. Sandeep Mehta weighs in on various diets and how they can help prevent and treat cardiovascular disease.
Sandeep Mehta, MD

Sandeep Mehta, MD

Scripps Center for Integrative Medicine
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California

Panel Discussion/Q&A 2

Drs. Mehta, Suhar and Uddin answer questions from course participants.
Christopher Suhar, MD

Christopher Suhar, MD

Division Head, Scripps Center for Integrative Medicine
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California
Poulina Uddin, MD

Poulina Uddin, MD

Director, Scripps Women’s Heart Center
General and Invasive Cardiology
Integrative and Holistic Medicine
Scripps Mercy Hospital San Diego
Scripps Clinic
La Jolla, California
Sandeep Mehta, MD

Sandeep Mehta, MD

Scripps Center for Integrative Medicine
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California

Cardiometabolic Disease and Novel Therapies: SGLT2 Inhibitors and GLP1 Agonists

Dr. Daniel Einhorn provides a summary of novel therapies related to managing and treating diabetes and cardiovascular disease.
Daniel Einhorn, MD, FACP, FACE

Daniel Einhorn, MD, FACP, FACE

Medical Director, Diabetes Program
Scripps Whittier Diabetes Institute
Diabetes and Endocrine Associates
La Jolla, California

Update on Inflammation and Novel Biomarkers for Atherosclerosis

Dr. Douglas Triffon discusses the role inflammation plays in the development of cardiovascular disease and reviews several clinical trial outcomes related to available treatment options.
Douglas Triffon, MD, FACC, FNLA, FASE

Douglas Triffon, MD, FACC, FNLA, FASE

Scripps Center for Integrative Medicine
Medical Director, Lipid Clinic
Scripps Clinic
La Jolla, California

The Utility of Polygenic Risk Scores in Primary Prevention of Atherosclerotic Cardiovascular Disease

Dr. Amitabh Pandey discusses the pros and cons of using genetic testing in predicting atherosclerotic cardiovascular disease.
Amitabh Pandey, MD

Amitabh Pandey, MD

Assistant Professor of Molecular Medicine
The Scripps Research Institute
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California

Case Presentations and Panel Discussion

Daniel Einhorn, MD, FACP, FACE

Daniel Einhorn, MD, FACP, FACE

Medical Director, Diabetes Program
Scripps Whittier Diabetes Institute
Diabetes and Endocrine Associates
La Jolla, California
Amitabh Pandey, MD

Amitabh Pandey, MD

Assistant Professor of Molecular Medicine
The Scripps Research Institute
Division of Cardiovascular Disease
Scripps Clinic
La Jolla, California
Douglas Triffon, MD, FACC, FNLA, FASE

Douglas Triffon, MD, FACC, FNLA, FASE

Scripps Center for Integrative Medicine
Medical Director, Lipid Clinic
Scripps Clinic
La Jolla, California

Return to Main Menu »

Course Overview

Atherosclerotic cardiovascular disease is a common problem which may begin early in life and progress as a person ages. The atherosclerotic condition involves lipid deposition of the arterial wall, which involves the immune system, inflammatory mediators, and the endothelial system. Over time, if developing atherosclerosis is left untreated, it may be progressive and can result in several dangerous and life-threatening cardiovascular conditions including myocardial infarction, carotid artery disease and stroke, among others. While atherosclerosis can often be prevented through good lifestyle choices including proper diet and exercise, a number of therapeutic options are available for patients where lifestyle changes may not be enough.

Over the past several years there has been a substantial increase of clinical trials specifically dedicated to the management and treatment of atherosclerosis and underlying risk factors. These studies have generated comprehensive data on a large number of randomized patients and have led to new indications for medical therapies. Clinicians need to be familiar with these evolving clinical diagnoses and novel therapeutic options for their patients. The Scripps Cardiovascular Atherosclerosis conference is designed to offer a comprehensive summary of these new treatment options as well as to promote clinical awareness regarding prudent lifestyle and dietary choices to improve patient outcomes.

Educational Objectives

  • Identify cardiac risk factors and estimation of patients’ clinical risk.
  • Explain mechanism and indication of PCSK9 inhibitors and omega 3 fish oil.
  • Summarize mechanism and indication of SGL2 inhibitors as well as GLP1 agonists’ mechanisms of action and cite indications for use.
  • Describe the cardiovascular benefits associated with diet and exercise modifications.
  • Assess cardiac CT scoring and utility of coronary CTA.
  • Illustrate polygenetic risk scoring in primary prevention of atherosclerotic cardiovascular disease.

 

View Faculty Disclosures »